Category: Pharma & Biotech

World Health Organization Explores International Rescheduling of CBD at Expert Committee Meeting

by Todd | Oct 26, 2017 | General, Medical Cannabis, Pharma & Biotech, Research | 0 comments October 26, 2017 Raul Elizalde to speak before WHO Expert Committee on Drug Dependence review of the psychoactivity of CBD. On November 6th, the World Health Organization’s (WHO) Thirty-Ninth meeting of the Expert Committee on Drug Dependence will begin a 5-day agenda set to determine the potential for harm or dependance of 16 different substances, including cannabidiol (CBD). Medical Marijuana, Inc. subsidiary HempMeds® will have a representative speaking before the committee on the first day regarding CBD. While WHO recognizes the medical use of certain substances is indispensable in the treatment of many conditions and that they should be available to patients for such purposes, the committee is also tasked with determining which substances should be regulated or banned internationally as scheduled drugs. WHO has a part in two of the United Nation’s central drug control conventions – the 1961 Single Convention on Narcotic Drugs and 1971 Convention on Psychotropic substances. WHO is responsible for conducting the medical, scientific, and public health evaluation of potentially harmful substances to determine the UN’s role in regulating them. This is done through the thirteen member Expert Committee on Drug Dependence (ECDD). The committee is made up of an international panel of experts in the field of drug addiction and abuse. The ECDD evaluates the dependence-producing...

Read More

Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2017

SHARE THIS POST TORONTO, ONTARIO–(Marketwired – Oct. 19, 2017) – Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs in the medical cannabis and cannabinoid pharmaceuticals sectors, today announced its results for the fiscal year ended June 30, 2017. The Audited Financial Statements and Management’s Discussion and Analysis for the year ended June 30, 2017, may be viewed on SEDAR at www.sedar.com. “I am pleased with how our focus on developing and commercializing novel cannabinoid-based therapies has evolved over this past year,” said Craig Leon, Chief Executive Officer of Revive. “The value creating initiatives achieved for our medical cannabis and cannabinoid pharmaceuticals strategy such as the exclusive license and the research of cannabinoid-based therapies for liver diseases, the development of a unique delivery technology for cannabinoids, the relationships with scientific advisors, academia and industry, and the potential of future collaborations with companies seeking to develop and commercialize novel cannabinoid-based therapies effectively positions Revive in the medical cannabis and cannabinoid pharmaceuticals space for broad and large market opportunities.” Over the past year Revive has been focused on developing novel therapies that target the endocannabinoid system and building a robust cannabinoid-based product pipeline which includes early stage research and development programs with the advancement of cannabinoid-based therapies for liver diseases and potentially...

Read More

Emerald Health’s Two Cannabis Production Expansion Sites Progressing for Legalized Adult-Use Market in 2018

SHARE THIS POST Emerald submits applications to Health Canada for two significant production expansion projects, including one of Canada’s largest-scale greenhouse operations Victoria, BC, October 18, 2017 – Emerald Health Therapeutics Inc. (“EHT”) (TSXV: EMH; OTCQX: EMHTF), through Emerald Health Botanicals Inc. (“Emerald”), its wholly owned subsidiary and a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), has submitted license applications to Health Canada for approval of two new growing sites. Emerald is preparing for the large-scale production of cannabis in anticipation of legalization of the adult-use cannabis market on July 1, 2018. In September, Emerald filed an application to Health Canada for its Pure Sunfarms’ Delta, BC facility, which is a partnership with Village Farms (TSXV: VFF). This partnership combines Emerald’s extensive medical cannabis growing experience and broad portfolio of cannabis genetics with Village Farms’ many decades of greenhouse growing expertise and large-scale, quality, low-cost production of an array of plant products and a currently producing, highly efficient 25-acre, 1.1 million square feet greenhouse facility. Emerald and Village Farms are retrofitting this greenhouse from tomato growing into a configuration optimized for largescale cannabis cultivation. With a key goal of the partnership to be a large, very low-cost cannabis producer, Pure Sunfarms also optioned from Village Farms an additional 3.7 million square feet of existing highly efficient greenhouse space in the same Delta complex. In...

Read More

Supreme Pharmaceuticals Announces Upsize of Previously Announced Bought Deal Private Placement to $35 Million

SHARE THIS POST October 18, 2017 Download this Press Release PDF Format (opens in new window) /NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ TSXV: FIRE TORONTO, Oct. 18, 2017 /CNW/ – Supreme Pharmaceuticals Inc. (the “Company”) (TSXV:FIRE) announced today that it has amended its agreement with Canaccord Genuity Corp., as lead underwriter on behalf of a syndicate of underwriters (the “Underwriters”), to increase the size of its previously announced bought deal private placement of convertible debenture units (the “Convertible Debenture Units”) to $35,000,000. Under the terms of the amending agreement, the underwriters will now have an option to acquire up to 5,250 additional Convertible Debenture Units, each having the same terms as the Convertible Debenture Units above, which option is exercisable until the Closing Date (as hereinafter defined).  All other previously announced terms of the Offering (as hereinafter defined) remain unchanged. As previously announced, each Convertible Debenture Unit will consist of $1,000 principal amount of 8.0% senior unsecured convertible debentures (the “Convertible Debentures”) and 313 common share purchase warrants (the “Warrants”) of the Company (the “Offering”). The Convertible Debentures will bear interest from the date of closing at 8.0% per annum, payable annually in arrears on December 30, 2018 and thereafter semi-annually on the last day of June and December in each year and will mature two years following the closing of the Offering (the...

Read More

MYM Enters Partnership to Build one Million Square Foot Cannabis Production Facility in Australia

SHARE THIS POST October 18, 2017 |In News |By cris UNCODE.initHeader(); MYM Nutraceuticals Inc. (CSE: MYM) (OTC: MYMMF) (the “Company” or “MYM”) is pleased to announce that it has entered into a strategic partnership with PUF Ventures Inc. (CSE: PUF) (Frankfurt: PU3) (OTCPK: PUFXF) (“PUF”) for the construction of a one million square foot greenhouse facility in northern New South Wales Australia called the Northern Rivers Project. The Northern Rivers Project is a partnership with the Richmond Valley Council—the local government in New South Wales, Australia—and PUF Ventures Australia (“PVA”)—a recently formed majority-owned subsidiary of PUF—to construct a one million square foot greenhouse operation, with large-scale manufacturing, processing and office facilities for the cultivation, production and manufacture of medical cannabis and associated products. MYM will own 35% of the Northern Rivers Project, which, at full scale, will have the capacity to produce 100,000 kilograms of high quality cannabis per year, worth between C$800 million and C$1.1 billion (based on current pricing metrics in the Australian cannabis marketplace). Australia has introduced progressive medical cannabis laws in the past few years, and are essentially where Canada was four years ago. Assuming recreational cannabis becomes legal and with a population of more than 24 million people, it is estimated that the cannabis market in Australia will grow to C$9 billion over the next 7 years making it a very attractive market. Being...

Read More